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INTRODUCTION: 
Humans sleep approximately one-third of their lives. 
Natural sleep patterns show considerable individual 
variability. Most adults are comfortable with 6.5-8 hours 
of sleep daily, taken in a single period.
1
 Scientists do not 
fully understand the necessity for sleep, nor the 
mechanisms for sleep‟s physical and mental restoration. 
Sleep deprivation creates fatigue and suboptimal 
performance, causing significant medical, psychological, 
and social disturbances.
2, 3 
Insomnia is the second most common medical complaint 
with almost one half of the older adults experiencing 
symptoms of insomnia on a few nights a week Insomnia 
is an inability to get the amount of sleep needed to 
function efficiently during the daytime. People with 
insomnia will often experience difficulty falling asleep, 
frequent awakenings during the night, early morning 
awakenings, insufficient sleep, day time exhaustion, lack 
of concentration, nervousness, depression and 
forgetfulness. It affects millions of people about one-
third of the adults in the United States. Many older 
people suffer from insomnia since it tends to increase 
with age and occur more frequently in people over age 
60. 
Insomnia is rarely a “primary disease”-meaning an 
isolated medical or mental illness-but rather a symptom 
of another illness to be investigated by a person and their 
medical doctors. In other people, insomnia can be a 
result of a person‟s lifestyle or work schedule. 
There are different types of insomnia. Insomnia can be 
caused by many different conditions other than age, for 
example, an underlying physical or medical problem, 
stress, depression or other mental disorder, 
environmental noise, extreme temperatures, a change in 
the surrounding environment, medication side effects, 
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shift work or other night-time activity schedules, or jet 
lag. 
Management of acute insomnia has traditionally 
involved pharmacotherapy. The use of such agents is 
common practice for both acute and chronic insomnia. 
Despite the fact that the benzodiazepines (BZP) such as 
temazepam and diazepam are used in the treatment of 
insomnia but on chronic use they are associated with 
tolerance, dependence, residual daytime sedative effects, 
cognitive and psychomotor impairment, and 
discontinuation syndromes including rebound insomnia 
and withdrawal symptoms. For this reason, BZD use 
should be judicious and is replaced by Zolpidem, a novel 
non-benzodiazepine hypnotics of Imidazopyridine class 
that has various advantages over benzodiazepines. 
Chronic administration of zolpidem produces neither 
tolerance to its sedative effects nor signs of withdrawal 
when the drug is discontinued. Also it has little effect on 
the stages of sleep in normal human subjects. The drug is 
as effective as benzodiazepines in shortening sleep 
latency and prolonging total sleep time in patients with 
insomnia. Tolerance and physical dependence develop 
only rarely and under unusual circumstances. So 
Zolpidem is an effective option with a reduced risk for 
dependence in the treatment of insomnia. 
Definition of insomnia: Diagnostic criteria:-
4 
DSM-IV defines insomnia as difficulty initiating sleep or 
maintaining sleep or having non-restorative sleep for 1 
month or more. The insomnia or resulting sleepiness 
must cause clinically significant impairment or distress 
in social, occupational, or other important areas of 
functioning. 
International Classification of Diseases ICD-10 (1992) 
defines insomnia as Difficulty falling asleep, maintaining 
sleep or Non-refreshing sleep for 3 times a week and for 
longer than 1 month. There is marked personal distress 
or interference with personal functioning in daily living. 
International Classification of Sleep Disorders (ICSD) 
and Research Diagnostic Criteria for Insomnia 
(RDC)
5 
defines insomnia as Difficulty  initiating sleep, 
maintaining sleep, waking up too early or  sleep is 
chronically non-restorative or poor in quality and Occurs 
despite adequate opportunity and circumstances for 
sleep. And, there is 
At least one form of daytime impairment 
i. Fatigue or malaise 
ii. Attention, concentration, or memory impairment 
iii. Social or vocational dysfunction or poor school 
performance 
iv. Mood disturbance or irritability 
v. Daytime sleepiness 
vi. Motivation, energy, or initiative reduction 
vii. Proneness for errors or accidents at work or while 
driving 
viii. Tension, headaches, or gastrointestinal symptoms in 
response to sleep loss 
ix. Concerns or worries about sleep. 
Epidemiology of insomnia:- 
Insomnia is the most common sleep disorder and one of 
those with the greatest health and social significance. 
The patient with insomnia complains primarily of 
dissatisfaction with the quality and or quantity of sleep. 
This dissatisfaction may stem from the difficulty in 
falling or staying asleep throughout the night, or the 
number of times patients wake up during the night. 
To understand the epidemiology of insomnia it helps to 
understand the clinical relevance of this disorder. 
Prevalence of Insomnia:- 
Insomnia, or inability to sleep, is the most commonly 
reported sleep problem in the industrialized world.
6
 
Estimates suggest that between 40 and 70 million 
Americans are affected by either intermittent or chronic 
sleep problems, representing approximately 20 percent of 
the population.
7
 The Sleep in America Poll, conducted 
by the National Sleep Foundation, revealed that almost 
50 percent of people surveyed had complaints of 
frequent insomnia, but only 6 percent were formally 
diagnosed.
8 
Moreover, approximately, 30 to 35 percent 
of
 
respondents complained of nightly insomnia.
 
The most 
prevalent symptoms of insomnia,
 
experienced at least a 
few nights a week by
 
people with insomnia, include 
waking up feeling
 
unrefreshed (34%) and being awake 
often
 
during the night (32%). The symptoms
 
of difficulty 
falling asleep and waking up too
 
early are less common, 
but still experienced at
 
least a few nights a week by about 
one-fourth of
 
adults with insomnia (23 to 24%). 
There is emerging evidence that short-term sleep 
deprivation, under strict experimental conditions, is 
associated with a variety of adverse physiological and 
cognitive effects. Decrements in memory, concentration 
and executive function have been reported. There is also 
an increased risk of injury and accidents. Physiological 
effects resulting from sleep deprivation include 
hypertension, activation of the sympathetic nervous 
system, altered glucose metabolism and increased 
inflammatory markers. Sleep deprivation is associated 
with excessive sleepiness. Acute insomnia, however, 
may not equate to sleep deprivation. There is no 
evidence to suggest that patients with insomnia 
experience similar changes. Furthermore, it is not yet 
clear from the evidence what the physiological 
consequences of chronic insomnia are or if there is a 
process of adaptation that occurs in individuals with 
chronic insomnia. Thus, further research is needed in the 
area of chronic insomnia to determine what impact 
chronic insomnia has on health. 
Risk Factors for Insomnia:- 
Although some risk factors and etiologies of insomnia 
have been identified, the nature of the relationships has 
not been fully elucidated. Some risk factors for insomnia 
that have emerged from data related to insomnia include 
female gender and old age.
9
 Additional risks factors 
include:- 
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 Medical disorders: CHF, COPD, asthma, GERD, 
cancer, chronic pain, hyperthyroidism, BPH, 
Parkinson‟s disease, fibromyalgia. 
 Primary sleep disorder: OSA, RLS, periodic limb 
movement disorder. 
 Psychiatric disorders 
 Sleep wake disorders: Irregular sleep-wake cycle, 
jet lag, shift work. 
 Substance Abuse 
 Medications: Anticholinergics, antidepressants, 
antiepileptic, CNS stimulants, steroids, 
bronchodilators, diuretics, etc. 
Classification of Insomnia:- 
There are many ways to classify insomnia, but for 
practical purposes they can be classified according to 
etiology, time of night when it occurs or duration. 
According to etiology:- 
 Primary insomnia:- Which doesn‟t have a clearly 
identifiable etiological factor or is not associated 
with any other medical condition. 
 Secondary insomnia:- SI is the term given to cases 
of insomnia that appear to be secondary to other 
distressful conditions or secondary to substance use. 
„Secondary‟ in this context means that another 
condition causes and maintains the insomnia. 
Insomnia cases where no causal link exists, but 
where insomnia and another condition co-occur yet 
function independently, are referred to as „co-
morbid‟. If an insomnia state is clearly secondary to 
another condition, then presumably, the insomnia 
will subside if the primary condition is successfully 
treated, but data to support this SI conceptual 
scheme are scarce, calling into question the concept 
of causal influence in supposed SI. 
According to duration:- 
 Transient insomnia:- Lasting less than a week. 
This is the most common and widespread form 
among the population. In a period of one year, about 
one-third of adult population have a problem with 
insomnia, and, of those, about halve have what is 
known as transient insomnia. It is often associated 
with precipitating stressors (e.g. environmental 
causes, sudden changes in sleeping time, occasional 
physical stress, and emotional crisis) and when they 
disappear sleep returns to normal. 
 Short term or acute insomnia:- Lasting between 
one and four weeks. It is related to stress factors, but 
longer lasting than for transitory insomnia. 
 Chronic insomnia:- Lasts for four or more weeks 
and may be due to intrinsecal cause in the organism 
e.g. a long term physical or psychiatric illness or it 
may have no apparent underlying cause.  
According to time of night when it occurs:- 
 Falling asleep:- The patient‟s complaints refer to 
difficulties in starting sleep. This is the most 
common form of insomnia associated with medical 
problems, drug abuse, or certain psychiatric disorder 
such as anxiety disorder. Such types of insomnia 
usually occur in the young. 
 Staying asleep:-the patient has difficulty in 
maintain sleep with frequent interruption or 
wakefulness during the night. It is common in cases 
of psychological or medical problems associated 
with ageing. 
 Waking up early:-when waking occurs at least two 
hours earlier than normal. 
Other Classification of Insomnia:- 
 Adjustment Insomnia 
 Psycho physiological Insomnia 
 Paradoxical Insomnia 
 Idiopathic Insomnia 
 Insomnia Due to Mental Disorder 
 Inadequate Sleep Hygiene 
 Behavioural Insomnia of Childhood 
 Insomnia Due to Drug or Substance 
 Insomnia Due to Medical Condition 
 Insomnia Not Due to Substance or Known 
Physiological Condition, Unspecified (Nonorganic 
Insomnia, NOS) 
 Physiological (Organic) Insomnia, Unspecified. 
Symptoms of insomnia:- 
 Difficulty falling asleep 
 Frequent awakenings during the night 
 Early morning awakenings 
 Insufficient sleep 
 Daytime exhaustion 
 Lack of concentration 
 Grouchiness or nervousness 
 Depression 
 Forgetfulness 
 Fatigue 
  Excessive Daytime Sleepiness 
  Major and/or Minor Depressive Episode 
 Generalized Anxiety Disorder 
 Memory/Concentration 
  Pain  
The assessment of insomnia:- 
An insomnia assessment includes a thorough sleep, 
medical and psychiatric history.
10 
The sleep history can 
begin with a chronological review of sleep starting with 
childhood and may also include: identifying any factors 
that precipitated the insomnia (and whether these factors 
are still present), current life stressors, factors currently 
thought to be contributing to insomnia, a description of a 
typical 24-hr period in terms of sleep behaviours and 
schedule, how often a typical night occurs, how a bad 
night differs from a good night, if there are any 
identifiable weekly, monthly or seasonal sleep patterns, 
what has been tried to correct the sleep disturbance and 
to what extent such strategies worked. A sleep history 
also includes questions to rule out other possible sleep 
disorders. Differential diagnosis also includes 
distinguishing the primary insomnias from a co-morbid 
insomnia. Some of these conditions do warrant targeted 
intervention prior to treating the presenting insomnia. 
Typical exclusions for initiating insomnia treatment 
include untreated or unstable medical, psychiatric or 
substance abuse conditions (e.g., gastroesophageal reflux 
disease, cardiopulmonary disorders, seizure disorders, 
some neuroendocrine disorders, sleep apnoea, bipolar 
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disorder, severe mental illness, active substance 
dependence). It is imperative to note that co-morbid 
insomnia may nonetheless be treated in conjunction with 
the treatment of a „primary‟ disorder or even as a front 
line intervention. Numerous self-report instruments exist 
for the assessment of sleep disturbance. Among the most 
widely used are the Pittsburgh Sleep Quality Index,
 11
 
which provides a global assessment of sleep, and the 
Insomnia Severity Index, 
12
 specifically designed for 
insomnia. Perhaps the most useful self-report measure is 
a daily sleep diary, which patients are asked to complete 
on a daily basis for 1-2 wk. At a minimum, a sleep diary 
assesses time to bed, minutes to fall asleep, number and 
duration of awakenings, final awakening and time out of 
bed. From these data, averaged over the 1-2 wk period, a 
patient‟s sleep continuity can be determined. This 
includes latency to sleep, wake time, average time in 
bed, total sleep time, sleep efficiency (sleep time divided 
by time in bed). Objective measures of sleep can be 
obtained via wrist-worn actigraphy. Although not as 
informative as a full night polysomnograhic recording, 
actigraphy can corroborate or replace sleep diary data. 
Unless paradoxical insomnia or another sleep disorder 
(e.g., sleep apnoea) is suspected, polysomnography is not 
indicated in the assessment of insomnia. An important 
consideration for the general, family, or other primary 
care practitioner is that any evaluation of sleep is not the 
norm in standard practice. Therefore, even asking a 
simple question such as “how are you 
Sleeping?” can begin to unmask chronic insomnia. Given 
the prevalence of insomnia, this can be a valuable 
conversation starter that leads to a more thorough sleep 
assessment or a referral based on the providers 
preference for managing insomnia in their practice.
  
Insomnia severity index:- 
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Pathophysiology of insomnia:- 
There is currently no single, cognitive-behavioural model 
of insomnia. Instead, a number of related and 
overlapping models are available. All such models 
consider insomnia a condition that develops over time, is 
related to maladaptive behaviours and cognitions, and 
becomes chronic unless treated aggressively in its acute 
phase. Spielman and colleagues
13
 set forth what has 
become known as the „3-P Model‟ of insomnia, which is 
essentially a diathesis-stress model. The model suggests 
that (i) individuals may be primed to develop insomnia 
by individual predisposing characteristics, such as 
various forms of hyperarousal and/or tendency to worry 
or ruminate, (ii) precipitating factors, such as stressful 
life events and/or new illness, initiate an episode, and 
(iii) predisposing factors, such as maladaptive coping 
strategies like napping or extending time in bed beyond 
the usual sleep window despite being asleep less, result 
in conditioned arousal and chronic insomnia. 
Hyperarousal, circadian dysrhythmia, and homeostatic 
dysregulation of sleep are each thought to contribute to 
the occurrence of insomnia. The largest body of work 
exists for hyperarousal conceptualized as either elevated 
basal levels or as a failure to downregulate at night and 
further construed along somatic/ physiologic, cognitive, 
and cortical/neurophysiologic dimensions.
14
 In terms of 
physiologic arousal, patients with insomnia have been 
shown to have elevations of heart rate, galvanic skin 
response, sympathetic arousal (as measured by heart rate 
variability), and increased hypothalamic-pituitary-
adrenal (HPA) axis activity. In terms of cognitive 
arousal, patients with insomnia are more prone to 
generalized worry, sleep-related worry, and selectively 
attend to and monitor insomnia symptoms. In terms of 
cortical/neurophysiologic arousal patients with insomnia 
exhibit increased high frequency EEG activity at or 
around sleep onset and during non-rapid eye movement 
(REM) sleep, elevated whole brain metabolism across 
waking and non-REM sleep
15
, and smaller metabolic 
declines than normal in the ascending reticular activating 
system, in the hippocampus, the amygdala and anterior 
cingulated cortex during the wake to sleep transition.
16
 
As
 
far as circadian dysregulation is concerned, research 
suggests that chronobiologic abnormalities, in the form 
of phase shifts of the core-body temperature rhythm, are 
/related to sleep initiation or maintenance problems. 
These shifts are similar to but smaller than those seen in 
full-fledged circadian rhythm disorders of sleep. It 
actually reset the “biological clock”. Patients with 
Primary Insomnia, as compared to good sleepers, tend to 
exhibit homeostatic abnormalities. First, sleep propensity 
is measured by the multiple sleep latency test
17
 (MSLT) 
in which mean time to fall asleep across successive 
daytime napping opportunities represent the level of 
objective sleepiness or sleep drive. Given that patients 
with insomnia tend to have less total sleep time than 
good sleepers, they would be expected to have shorter 
sleep latencies on the MSLT. Most MSLT studies have 
shown that patients with insomnia have normal, or longer 
than normal sleep latencies
18
. This suggests a possible 
reduction in sleep drive, and by inference, a faulty sleep 
homeostat. Second, patients with insomnia have less 
slow wave sleep (SWS) than good sleepers, by itself 
diminished SWS does not directly implicate homeostatic 
dysregulation. Third, following sleep deprivation patients 
with insomnia show diminished SWS, a cardinal 
homeostatic response to sleep loss.  
Consequences of insomnia:- 
 Worsens psychiatric disorders 
 Prolongs medical illnesses 
 Reduced quality of life 
 Higher absenteeism 
 Increased accident risk 
 Higher health care costs 
 Cognitive impairment 
 
 
Car accidents and Sleep disorders:- 
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Economic impact of insomnia:- 
 Direct Cost 
 Drugs: $1.97 Billion (41% prescription) 
 Services: $11.96 Billion 
 Indirect Costs 
 Decreased productivity 
 Higher accident rate 
 Increased absenteeism 
 Increased co-morbidity  
 Total Annual Cost: $30-$107 billion 
Management of insomnia:- 
After evaluating any medical and psychiatric problems, 
physician‟s primary goals are to remove or mitigate these 
underlying problems, to prevent progression from 
transient to chronic insomnia, and to improve the 
patient‟s quality of life. Achieving these goals involves 
educational, behavioural, and often pharmacologic 
intervention. 
Pharmacotherapeutic Management:- 
Until the advent of the non-benzodiazepine hypnotics, 
the most commonly used agents were benzodiazepines. 
Currently approved benzodiazepines for the treatment of 
insomnia are flurazepam, triazolam, quazepam, 
estazolam, and temazepam. Although, both subjective 
and objective studies have generally found 
improvements in sleep maintenance measures, 
specifically wake time after sleep onset and number of 
awakenings, with the longer-acting agents like 
flurazepam, quazepam, and estazolam
19
. Their use, 
however, is also associated with next-day sedation and 
impaired cognitive and psychomotor function, ataxia, 
slurred speech, inattention, risk of tolerance, abuse, 
withdrawal syndrome and dependence following 
extended use
20
.
 
So, benzodiazepines have not been 
satisfying due to these associated side effects. And, these 
are the major limiting factors for their use. 
Over the past years we have observed clinical and 
scintigraphic improvement in insomnia patients after 
administration of 10 mg zolpidem with reduced risk of 
tolerance, dependence and rebound insomnia. 
Zolpidem:- 
Zolpidem (N, N, 6-trimethy l-2 [4-methyl-phenyl] 
imidazo [1, 2-a] pyridine-3-acetamide hemitartrate) is a 
stable, water-soluble, microcrystalline solid with a 
molecular weight of 392.4 (weight of salt). Its structural 
formula is shown in Fig 1. The medicinal chemistry 
program that led to the discovery of zolpidem an 
Imidazopyridine derivates has been described by George 
et al.
21  
The aim of the drug discovery program that led to 
zolpidem was to identify a non-benzodiazepine 
compound that would show a rapid-onset, short-duration 
hypnotic effect and would bind to benzodiazepine (BZ) 
receptors. Zolpidem has these characteristics
22
, but 
during the course of the pharmacological evaluation of 
the compound it was found that both, its pharmacological 
profile and its mechanism of action, differed in 
potentially significant ways from those of the 
benzodiazepines themselves. 
 
Fig 1:  Zolpidem; N, N-dimethyl-2-(6-methyl-2-p-
tolylimidazo[1,2-a]pyridin-3-yl) acetamide 
Mechanism of action:- 
Zolpidem tartrate belongs to the Imidazopyridine group 
of compounds and is structurally unrelated to other 
hypnotic agents. Zolpidem tartrate selectively binds the 
omega-1 receptor subtype (also known as the 
benzodiazepine-1 subtype) which is the alpha unit of the 
GABAA receptor complex. Whereas benzodiazepines 
non-selectively bind all three omega receptor subtypes, 
zolpidem tartrate preferentially binds the omega-1 
subtype. The modulation of the chloride anion channel 
via this receptor leads to the specific sedative effects 
demonstrated by zolpidem tartrate i.e. the preservation of 
deep sleep (stage 3 and 4 slow wave sleep). 
Pharmacokinetic properties:- 
It has both a rapid absorption and onset of hypnotic 
action. Peak plasma concentration is reached at between 
0.5 and 3 hours. Following oral administration, 
bioavailability is 70% due to a moderate first pass 
metabolism. The elimination half-life is short, with a 
mean value of 2.4 hours (+ 0.2 h) and a duration of 
action of up to 6 hours. Its pharmacokinetic profile is 
linear in the therapeutic dose range, and is not modified 
upon repeated administration. 
Protein binding amounts to approximately 90%. The 
volume of distribution in adults is 0.54 ± 
0.02 L/kg and decreases to 0.34 ± 0.05 L/kg in the very 
elderly. The main cytochrome P450 enzyme involved in 
the hepatic biotransformation of zolpidem tartrate is 
CYP3A4. CYP1A2 and CYP2D6 contribute minimally 
to the metabolism of zolpidem. All metabolites are 
pharmacologically inactive and are eliminated in the 
urine (56%) and in the faeces (37%). Furthermore, they 
do not interfere with zolpidem tartrate plasma binding. 
Zolpidem tartrate did not accumulate in young adults 
following nightly dosing with 20 mg zolpidem tartrate 
tablets for 2 weeks. 
A food-effect study in 30 healthy male volunteers 
compared the pharmacokinetics of zolpidem tartrate 10 
mg when administered while fasting or 20 minutes after 
a meal. Results demonstrated that with food, mean AUC 
and Cmax were decreased by 15% and 25%, respectively, 
while mean Tmax was prolonged by 60% (from 1.4 to 2.2 
hr). The half-life remained unchanged. These results 
suggest that, for faster sleep onset, ZOLPIDEM should 
not be administered with or immediately after a meal. 
In the elderly, the recommended dose for ZOLPIDEM is 
5 mg. This recommendation is based on several studies 
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in which the mean Cmax, T1/2 and AUC were significantly 
increased when compared to results in young adults. 
Zolpidem tartrate did not accumulate in elderly subjects 
following nightly oral dosing of 10 mg for 1 week. 
Efficacy of zolpidem in Insomnia:- 
Zolpidem was first introduced to the market as a short-
term treatment for insomnia in France in 1988. It has 
subsequently been registered in > 70 countries. It was 
first marketed in the United States in 1993. In some 
countries, zolpidem is the most widely prescribed and 
used hypnotic drug. A large number of clinical studies of 
the efficacy of zolpidem in inducing and maintaining 
sleep, involving tens of thousands of patients, have been 
carried out and the results have been published. Several 
detailed reviews of this literature are available.
23, 24, 25
  
Zolpidem‟s activity has been evaluated using subjective 
assessments in which patients responded to 
questionnaires concerning the latency, quality, and 
duration of their sleep. In such studies, zolpidem was 
reported to reduce sleep latency, increase duration, and 
produce more satisfying sleep. These findings have been 
confirmed in trials using objective polysomnographic 
methods in which sleep latency and nocturnal 
awakenings were reduced and sleep duration was 
increased. These studies have also reported that sleep 
architecture was not disrupted during a night of 
zolpidem-assisted sleep. Analyses of the microstructure 
of sleep have also been carried out using measures of the 
cyclic alternating pattern (CAP). CAP rate is 
significantly correlated with the subjective appreciation 
of sleep quality even in the absence of significant 
macrostructural alterations.
26
 Zolpidem was found to 
reduce the increased CAP rate shown in the disturbed 
sleep of insomniac patients and to attenuate the 
instability of the sleep patterns produced by noise.
27 
In 
seeking to develop zolpidem as a rapid-onset, short-
duration hypnotic, a major aim
 
was to identify a drug that 
would not give rise to impairments in performance the 
day after
 
a night of drug-assisted sleep. Such next-day 
effects have been a significant cause for
 
concern with 
some hypnotic barbiturates and benzodiazepines. A 
number of studies were
 
therefore carried out to 
investigate next-day alertness and psychomotor 
performance with
 
zolpidem.
28  
 The results of these 
studies showed that when appropriate
 
doses of zolpidem 
(5 to 10 mg) were taken at bedtime there were minimal 
effects
 
on cognitive or psychomotor performance or 
daytime drowsiness the next morning. 
Safety of zolpidem in Insomnia:- 
Before registration and marketing, zolpidem was tested 
in the appropriate toxicological screens in experimental 
animals. The results showed that the compound was 
extremely well tolerated with a large therapeutic ratio.
29
 
In the clinic, controlled trials and postmarketing 
surveillance have confirmed the positive safety profile.
30, 
31, 32 
Zolpidem is also safe in overdose; Garnier et al.
33
 
reported in a review of 344 cases of intentional, acute 
overdose that the effects were generally benign, 
requiring no specific measures except support and 
perhaps gastric lavage. In post-marketing surveys most 
reported adverse events were CNS related and not 
unexpected for a hypnotic drug       (e. g. drowsiness or 
sedation). Gastrointestinal events such as nausea are also 
reported occasionally, particularly at higher doses. It has 
been suggested, in fact, that such effects may limit the 
abuse potential of zolpidem. Rebound insomnia 
following cessation of a course of hypnotic treatment, 
which has been reported to be a problem with some other 
drugs in this class, is also of minimal significance when 
zolpidem is used at the correct doses and for an 
appropriate duration
34
. It has various advantages over 
benzodiazepines. Its higher selectivity towards α-1 
subunits of the GABAA receptor can be identified as 
cause of more specific sleep-related actions and 
reduction of some undesired adverse effects. Although 
chronic administration of zolpidem produces neither 
tolerance to its sedative effects nor signs of withdrawal 
when the drug is discontinued. Unlike the 
benzodiazepines, zolpidem has little effect on the stages 
of sleep in normal human subjects. The drug is as 
effective as benzodiazepines in shortening sleep latency 
and prolonging total sleep time in patients with insomnia. 
After discontinuation of zolpidem, the beneficial effects 
on sleep reportedly persist for up to 1 week. Tolerance 
and physical dependence develop only rarely and under 
unusual circumstances.
35, 36
 Indeed, zolpidem-induced 
improvement in sleep time of chronic insomnia was 
sustained during as much as 6 months of treatment 
without signs of withdrawal or rebound after stopping 
the drug.
37
 Nevertheless, zolpidem is approved only for 
the short-term treatment of insomnia. 
CONCLUSION: 
Insomnia is the most common sleep disorder. The 
inability to attain restful sleep in adequate amounts 
imposes a host of negative consequences. Its impact on 
financial, social
 
and psychological status of patients and 
their caregivers cannot be ignored. Moreover, there is 
large degree of morbidity (medical and psychiatric) that 
comes with chronic insomnia. Thus finding a novel way 
to tackle these health problems is the need of present 
times. Although, Conventional treatment for insomnia 
includes drugs that exert a depressant effect on the CNS, 
and psychological therapy. Most of the drugs prescribed 
for insomnia involve some risk of overdose, tolerance, 
habituation, and addiction. So, as alternative therapies, 
zolpidem a novel non-benzodiazepine is an effective 
option with a reduced risk for dependence in the 
treatment of insomnia. Zolpidem is less likely to have the 
drawbacks of conventional drugs. Patients who suffer 
from longer term insomnia and have predominantly sleep 
maintenance problems, such as those with psychiatric or 
medical illnesses, are particularly challenging for 
clinicians, because little research has been conducted in 
these patient populations with either behavioural therapy 
or pharmacotherapy. Although zolpidem is an effective 
option with reduced risk for tolerance, rebound 
phenomenon and dependence, and has a positive impact 
on subjective next-day functioning, more research is 
needed to improve the therapeutic armamentarium for 
difficult-to-treat patients as well as to determine the 
long-term benefits of treating insomnia. 
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